Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Dr. Carlo Tanzi of Investor Relations. Please go ahead. Thank you and good morning. Today, before market opens, We issued a press release with our third quarter 2025 financial results and business updates available on the investors and news section of our website. We've also posted an updated corporate presentation. Before we begin, I'd like to remind everyone that we're making forelooking statements, including statements around the results of our current or planned clinical trials, studies, and data readouts, our product candidates and their potential benefits, development plans, and potential commercial opportunities, interactions with and feedback from the FDA, our ability to secure an R&D or other partnership and or generate or obtain additional capital, financing, or other resources, our plan's strategic focus and operating plans, cost reduction actions and anticipated benefits and cash runway, the timing of and the foregoing, and other statements which are not historical facts. Actual results may differ materially due to various risks and uncertainties, and other important factors described under risk factors in our recent SEC filings. We undertake no obligation to update these statements except as required by law. On today's call with prepared remarks are Mirela Thorell, our co-chief executive officer and chief financial officer, and Dr. Matthew Henn, our chief scientific officer. Additional members of the management team, including Tom DeRosier, co-CEO and chief legal officer, Terry Young, chief commercial and strategy officer, and Dr. Dennis ...